^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    pomalidomide

    i
    Other names: CC 4047, CDC 394, CC-4047 , CDC-394
    Company:
    Generic mfg.
    Drug class:
    TNFα inhibitor, IL-6 inhibitor, NK cell stimulant, IL-10 stimulant, IL-1β inhibitor
    Related drugs:
    9ms
    Ciltaca-cel significantly improved PFS over SOC pomalidomide, bortezomib, & dexamethasone or daratumumab, pomalidomide, & dexamethasone in pts w/ lenalidomide-refractory MM who received 1 to 3 prior lines of therapy. @bhemato @MedicalCollege #mmsm https://t.co/Pav2681nn1 (@OncLive)
    Clinical
    |
    lenalidomide • bortezomib • Darzalex (daratumumab) • dexamethasone • pomalidomide
    10ms
    Ciltaca-cel significantly improved PFS over SOC pomalidomide, bortezomib, & dexamethasone or daratumumab, pomalidomide, & dexamethasone in pts w/ lenalidomide-refractory MM who received 1 to 3 prior lines of therapy. @bhemato @MedicalCollege #mmsm https://t.co/CGAxsgJTiz (@OncLive)
    Clinical
    |
    lenalidomide • bortezomib • Darzalex (daratumumab) • dexamethasone • pomalidomide
    over1year
    Treatment with lenalidomide but not pomalidomide leads to expansion of preleukemic Trp53-mutant HSPCs due to selective degradation of Ck1α. >>>Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms https://t.co/uyLmo9GgcI #mmsm (@smbenlazar)
    TP53 (Tumor protein P53) • CSNK1A1 (Casein Kinase 1 Alpha 1)
    |
    TP53 mutation
    |
    lenalidomide • pomalidomide
    2years
    Pomalidomide-induced pulmonary toxicity in MM.CT:interstitial changes & bilateral upper lobe ground glass opacities.BAL: lymphocytosis w elevated CD4:CD8 ratio to lymphocyte depletion w reverse CD4:CD8 ratio w/wout eosinophilia.Treatment: Steroids #mmsm #MedTwitter #USMRC #MedEd (@Abdallah81MD)
    CD4 (CD4 Molecule)
    |
    pomalidomide
    over2years
    Role of MBD3-SOX2 axis in residual myeloma following pomalidomide https://t.co/hYY7zWAaj7 #mmsm (@AlGarfall)
    SOX2
    |
    pomalidomide
    over2years
    Structure of BMS' cereblon E3 ligase modulator CC-99282 presented. Compound shows 100% tumor regression at 30 mg/kg in DLBCL xenograft model and improved survival over pomalidomide in CNS lymphoma model #ACSFall2021 (@ClarivateHealth)
    CRBN (Cereblon)
    |
    pomalidomide • golcadomide (CC-99282)
    3years
    Role of MBD3-SOX2 axis in residual myeloma following pomalidomide: Implications for IMiD-PI synergy. https://t.co/PvV70tU6j0 (@PLMcCarthyMD)
    SOX2
    |
    pomalidomide
    3years
    Multiple cereblon genetic changes are associated with acquired #resistance to lenalidomide or pomalidomide in #MultipleMyeloma. @DrSarahGooding @NaserAnsariPour @pauladhiman @NBahlis @pvyas_oxford @OxfordBRC @bdi_oxford @MRC_WIMM #IMiD #haematology https://t.co/OCPkKNvX4z (@OxfordHaem)
    CRBN (Cereblon)
    |
    lenalidomide • pomalidomide
    over3years
    #Myeloma Paper of the Day: ARID2 is a pomalidomide-dependent CRL4 CRBN substrate in multiple #myeloma cells, andARID2 expression is associated with a poor prognosis: https://t.co/IOxcEd7wiJ. (@Myeloma_Doc)
    CRBN (Cereblon) • IL17RB (Interleukin 17 Receptor B)
    |
    pomalidomide